A study led by Loyola Medicine researchers may help reassure patients who worry the breast cancer drug tamoxifen could increase their risk of uterine cancer.
Sep 15, 2016
0
3
An animal study suggests that resistance to tamoxifen therapy in some estrogen receptor positive breast cancers may originate from in utero exposure to endocrine disrupting chemicals. The study provides a new path forward ...
Sep 8, 2016
0
0
Scientists may have unlocked the genetic code that determines why many patients with estrogen receptor-positive breast cancer fail to respond to the widely used drug tamoxifen.
Sep 7, 2016
0
0
Tiny bubbles filled with the sleep hormone melatonin can make breast cancer treatment more effective, which means people need a lower dose, giving them less severe side effects. In a new study published in Colloids and Surfaces ...
Jun 14, 2016
0
32
A study led by Loyola Medicine researchers may help reassure patients who worry the breast cancer drug tamoxifen could increase their risk of uterine cancer.
Jun 6, 2016
0
3
(HealthDay)—For premenopausal women with breast cancer, two years of tamoxifen is associated with long-term survival benefit, according to a study published online May 9 in the Journal of Clinical Oncology.
May 12, 2016
0
5
In a new study from Kaiser Permanente, researchers found the use of aromatase inhibitors, hormone-therapy drugs used to treat patients with breast cancer, was not associated with an increased risk of fatal cardiovascular ...
Apr 21, 2016
0
2
The drug anastrozole is effective in treating an early form of breast cancer, according to a clinical trial led by Queen Mary University of London (QMUL). The results of the IBIS-II DCIS trial show that anastrozole is as ...
Dec 11, 2015
0
2
Postmenopausal women with ductal carcinoma in situ (DCIS) had similar outcomes with disease recurrence whether they took tamoxifen or the aromatase inhibitor anastrozole for five years after surgery, but women in the two ...
Dec 11, 2015
0
4
The anti-hormone therapy tamoxifen can reduce breast cancer recurrence by about half in women with hormone-sensitive breast cancer. But it works better in some women than others. Researchers are not sure why.
Dec 10, 2015
0
28
